Mirvetuximab soravtansine · Elahere
Antibody–drug conjugate
Also known as IMGN853, TAK-853
Evidence outlook
Approved: Ovarian Cancer
Regulatory approval supersedes design-level evidence grading; the trials behind approval are preserved below as the drug's evidence history.
How the evidence outlook works ↗
Featured trials
The studies most instrumental to this drug's clinical progression, individually graded on design and result. The complete registry, including every study not featured here, is listed below.
Featured-trial selection for this indication is pending.
All registered studies
Every ClinicalTrials.gov study of this drug's own program. Studies backing a featured trial above are marked Featured; the rest aren't individually graded. Filter by which indication a study was run for, then browse by phase. Studies where this drug served as another program's comparator, or is merely referenced, are listed separately below.
Phase 3 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 2 (16)
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
What this study did
Phase 1/2 (2)
What this study did
What this study did
Phase 1 (5)
What this study did
What this study did
What this study did
What this study did
What this study did
Used as active comparator (1)
Other programs' studies in which this drug was the registered active-comparator arm: a marker of standard-of-care status, not evidence of this drug's own progression.
Phase 3 (1)
What this study did
Competitive landscape
This drug's own stage for Ovarian Cancer: Approved. Competitors below are sorted furthest-along first.
| Drug | Stage | Modality | Mechanism | Evidence signal | Reported efficacygraded featured trials | |
|---|---|---|---|---|---|---|
| Mirvetuximab Soravtansine (Elahere): this drug | Approved | Antibody–drug conjugate | — | not yet graded | No reviewed efficacy summary in this indication | |
| Avutometinib / Defactinib (Avmapki Fakzynja Co-Pack) | Approved | Small molecule | MEK1/2 and RAF (CRAF, BRAF), FAK | not yet graded | No reviewed efficacy summary in this indication | |
| BAT1706 (Avzivi) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Bevacizumab | Approved | Monoclonal antibody | VEGF-A, Vascular Endothelial Growth Factor Inhibitor | not yet graded | No reviewed efficacy summary in this indication | |
| Gemcitabine | ApprovedUS marketing discontinued | Small molecule | ribonucleotide reductase / DNA polymerase (dCTP competition) | not yet graded | No reviewed efficacy summary in this indication | |
| Jobevne (bevacizumab-Nwgd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Niraparib | Approved | Small molecule | PARP1/2 | Reliable signal | NCT02655016: Progression Free Survival (Up to 34 months): Placebo 8.2 Months (95% CI 7.3 to 8.5) | Niraparib 13.8 Months (95% CI 11.5 to 14.9) | |
| Olaparib | Approved | Small molecule | PARP | not yet graded | No reviewed efficacy summary in this indication | |
| Pembrolizumab | Approved | Monoclonal antibody | PD-1 | Reliable signal | No reviewed efficacy summary in this indication | |
| Relacorilant (Lifyorli) | Approved | Small molecule | Glucocorticoid receptor | Partial signal | No reviewed efficacy summary in this indication | |
| Rucaparib | Approved | Small molecule | PARP (poly ADP-ribose polymerase) enzymes, PARP1/2 | Reliable signal | Featured results are non-efficacy only in this race | |
| Vegzelma (bevacizumab-Adcd) | Approved | Monoclonal antibody | VEGF-A | not yet graded | No reviewed efficacy summary in this indication | |
| Durvalumab | Phase 3 | Monoclonal antibody | PD-L1 | not yet graded | No reviewed efficacy summary in this indication | |
| GSK 5733584 | Phase 3 | — | — | not yet graded | No reviewed efficacy summary in this indication | |
| INCB123667 | Phase 3 | Small molecule | CDK2 | not yet graded | No reviewed efficacy summary in this indication | |
| Izalontamab Brengitecan | Phase 3 | Antibody–drug conjugate | EGFR + HER3 | not yet graded | No reviewed efficacy summary in this indication | |
| Olvimulogene Nanivacirepvec | Phase 3 | Oncolytic virus | No discrete molecular target | not yet graded | No reviewed efficacy summary in this indication | |
| Raludotatug Deruxtecan | Phase 3 | Antibody–drug conjugate | CDH6 (Cadherin-6) | not yet graded | No reviewed efficacy summary in this indication | |
| Rinatabart Sesutecan (Rina-S) | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Sacituzumab Tirumotecan | Phase 3 | Antibody–drug conjugate | TROP2 | not yet graded | No reviewed efficacy summary in this indication | |
| Sofetabart Mipitecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Torvutatug Samrotecan | Phase 3 | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Brengitecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Trastuzumab Rezetecan | Phase 3 | Antibody–drug conjugate | HER2 | not yet graded | No reviewed efficacy summary in this indication | |
| Birinapant | Phase 2 | — | IAP (inhibitor of apoptosis) proteins | not yet graded | No reviewed efficacy summary in this indication | |
| Ixotatug Vedotin | Phase 2 | Antibody–drug conjugate | Claudin 6 (CLDN6) | not yet graded | No reviewed efficacy summary in this indication | |
| Stenoparib | Phase 2 | Small molecule | PARP1/2, Tankyrase 1/2 | not yet graded | No reviewed efficacy summary in this indication | |
| COM701 | Phase 1/2 | Monoclonal antibody | PVRIG (CD112R) | not yet graded | No reviewed efficacy summary in this indication | |
| REGN5668 | Phase 1/2 | Multispecific antibody | MUC16 x CD28 | not yet graded | No reviewed efficacy summary in this indication | |
| Rezatapopt | Phase 1/2 | Small molecule | p53 reactivator | not yet graded | No reviewed efficacy summary in this indication | |
| TUB-040 | Phase 1/2 | Antibody–drug conjugate | NaPi2b (sodium-dependent phosphate transporter, SLC34A2) | not yet graded | No reviewed efficacy summary in this indication | |
| Ubamatamab | Phase 1/2 | Monoclonal antibody | MUC16 x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| 27T51 | Phase 1 | Cell therapy | MUC16 | not yet graded | No reviewed efficacy summary in this indication | |
| ABBV-901 | Phase 1 | Undisclosed | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication | |
| APG-2449 | Phase 1 | Small molecule | FAK / ALK / ROS1 | not yet graded | No reviewed efficacy summary in this indication | |
| CRX100 | Phase 1 | Cell therapy | Cell-based oncolytic virus immunotherapy | not yet graded | No reviewed efficacy summary in this indication | |
| IDE-161 | Phase 1 | Small molecule | PARG | not yet graded | No reviewed efficacy summary in this indication | |
| XmAb541 | Phase 1 | Multispecific antibody | Claudin 6 (CLDN6) x CD3 | not yet graded | No reviewed efficacy summary in this indication | |
| Luveltamab Tazevibulin | Discontinued | Antibody–drug conjugate | Folate receptor alpha (FRα) | not yet graded | No reviewed efficacy summary in this indication |
Upcoming events
(11 total)
Estimated primary-completion dates from ClinicalTrials.gov. These are registry estimates, never confirmed readout dates; they can move as trials progress.
Follow Elahere (Mirvetuximab soravtansine) to get an email as a readout nears, when a date moves, or when a study changes status. Needs a free account.
Add these readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.